Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Neurofibrosarcoma 1Neoplasms, Connective and Soft Tissue 1Myosarcoma 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Histiocytoma 1Fibrosarcoma 1Chondrosarcoma 1

Interventions

Imatinib Mesylate 10Cyclophosphamide 9fludarabine 8nilotinib 7fludarabine phosphate 7Dasatinib 6Busulfan 6Whole-Body Irradiation 5Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Melphalan 5Cytarabine 5Stem Cell Transplantation 4Filgrastim 4Alemtuzumab 4Cyclosporine 3Bone Marrow Transplantation 3Antilymphocyte Serum 3thymoglobulin 2ruxolitinib 2ponatinib 2plerixafor 2bosutinib 2Thiotepa 2Sirolimus 2Granulocyte Colony-Stimulating Factor 2Everolimus 2venetoclax 1vatalanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT02543749 2023-02-09

DC Vaccination in CML

Charite University, Berlin, Germany

Phase 1/2 Terminated
1 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡